After the administration of E2HSA in each dose group, only a few subjects (about 8%) developed anti-E2HSA antibodies and anti-Exenatide-4 antibodies, and most subjects did not develop anti-drug antibodies with neutralizing drug activity, suggesting E2HSA is less likely to cause anti-drug antibodies after entering the human body, and less likely to affect the efficacy of the drug.